A Phase I Multicenter, Dose-Escalation Study of IDEC-152 (Anti-CD23 Monoclonal Antibody) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia.
Phase of Trial: Phase I
Latest Information Update: 02 Jun 2015
At a glance
- Drugs Lumiliximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Biogen
- 07 Jun 2017 Biomarkers information updated
- 04 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jun 2009 Planned end date (Dec 2010) added as reported by ClinicalTrials.gov.